1
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Condition(s):Breast CancerLast Updated:February 24, 2020Active, not recruiting
Fulvestrant: 307 Clinical Trials, Page 1 of 31
Hide Studies Not Open or Pending
2
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
Condition(s):Female Breast Carcinoma; Female Ductal Carcinoma In SituLast Updated:October 15, 2019Recruiting
3
Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.
Condition(s):Postmenopausal Women With ER+ HER2- Primary Breast CancerLast Updated:February 6, 2020Completed
4
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
Condition(s):Breast CancerLast Updated:February 15, 2019Recruiting
5
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
Condition(s):Breast CancerLast Updated:January 27, 2020Recruiting
6
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
Condition(s):Malignant Neoplasms of Female Genital OrgansLast Updated:August 26, 2019Recruiting
7
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Condition(s):Breast CancerLast Updated:June 25, 2020Active, not recruiting
8
Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects
Condition(s):HealthyLast Updated:March 9, 2017Completed
9
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
Condition(s):Metastatic Breast CancerLast Updated:February 12, 2020Recruiting
10
Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )
Condition(s):Breast Cancer; HER2-positive Breast CancerLast Updated:July 25, 2019Recruiting